chromosome 11 open reading frame 52Genealiases: []
Q-omics provides the consensus-scored C11orf52 profile across patient tissues and cancer cell-line models. C11orf52 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C11orf52 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, C11orf52 protein abundance shows 18,969 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, KICH, and PDAC as cancer lineages where C11orf52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf52 survival associations across molecular data types. C11orf52 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf52 RNA expression–survival associations across cancer types. High C11orf52 expression shows unfavorable associations in COAD, but favorable associations in KIRC, UCEC, LUAD, SKCM and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C11orf52 RNA expression.
This table summarizes C11orf52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C11orf52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf52 shows lower tumor expression in KICH, THCA, KIRC and LUSC and higher tumor expression in BLCA and LIHC. The KICH box plot shows higher C11orf52 RNA expression in normal versus tumor tissue (log2 FC = −1.043, t-test p < 0.001).
This table shows molecular features associated with C11orf52 in patient tissues and cancer cell lines. In patient samples, C11orf52 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf52 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BREAST.
